

## FAS

### Recombinant Human CD95 / TNFRSF6 (His Tag)

|                              |  |                  |                           |
|------------------------------|--|------------------|---------------------------|
| <b>Catalog No.</b>           | CRH416A-His<br>CRH416B-His<br>CRH416C-His  | <b>Quantity:</b> | 50 µg<br>100 µg<br>1.0 mg |
| <b>Alternate Names:</b>      | Tumor necrosis factor receptor superfamily member 6, Apo-1 antigen, Apoptosis-mediating surface antigen FAS, FASLG receptor, CD95  |                  |                           |
| <b>Description:</b>          | CD95 is an important inducer of the extrinsic apoptosis signaling pathway and therapy induced apoptosis of many tumor cells has been linked to the activity of CD95. is a prototype death receptor characterized by the presence of an 8 amino acid death domain in its cytoplasmic tail. This domain is essential for the recruitment of a number of signaling components upon activation by either agonistic anti-CD95 antibodies or cognate CD95 ligand that initiate apoptosis. The complex of proteins that forms upon triggering of CD95 is called the death-inducting signaling complex (DISC). The DISC consists of an adaptor protein and initiator caspases and is essential for induction of apoptosis. Changes in the expression of CD95 and/or its ligand CD95L are frequently found in human cancer. The downregulation or mutation of CD95 has been proposed as a mechanism by which cancer cells avoid destruction by the immune system through reduced apoptosis sensitivity. Thus, CD95 has therefore been viewed as a tumor suppressor. CD95 has been reported to be involved in the activation of NF-kappaB, MAPK3/ERK1, MAPK8/JNK, and the alternate pathways for CTL-mediated cytotoxicity. Accordingly, this protein is implicated in the pathogenesis of various malignancies and diseases of the immune system. The CD95/CD95L system was implicated in the etiology of inflammatory bowel disease (IBD) based, primarily, on the finding that CD95 is highly expressed in the intestinal epithelial cells and that epithelial apoptosis is increased in IBD. |                  |                           |
| <b>UniProt ID:</b>           | P25445   |                  |                           |
| <b>Accession Number:</b>     | NP_000034.1  |                  |                           |
| <b>Protein Construction:</b> | A DNA sequence encoding the extracellular domain (Met 1-Asn 173) of human FAS antigen was expressed, with a C-terminal polyhistidine tag.  |                  |                           |
| <b>Source:</b>               | HEK293 Cells   |                  |                           |
| <b>Molecular Weight:</b>     | The secreted recombinant human FAS comprises 159 amino acids and has a predicted molecular mass of 18.2 kDa. In SDS-PAGE under reducing conditions, the apparent Mr of rhFAS is ~30-40 kDa due to glycosylation.   |                  |                           |
| <b>Formulation:</b>          | Lyophilized from sterile PBS, pH 7.4<br>Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.   |                  |                           |
| <b>Purity:</b>               | > 95 % as determined by SDS-PAGE.  |                  |                           |
| <b>Endotoxin Level:</b>      | < 1.0 EU per µg of the protein as determined by the LAL method   |                  |                           |



Cell Sciences®

65 Parker Street

Unit 11

Newburyport, MA 01950

Toll Free: 888-769-1246

Phone: 978-572-1070

Fax: 978-992-0298

E-mail: [info@cellsciences.com](mailto:info@cellsciences.com)

Website: [www.cellsciences.com](http://www.cellsciences.com)

**Biological Activity:** Measured by its ability to inhibit Fas Ligand induced apoptosis of Jurkat human acute T cell leukemia cells. The ED50 for this effect is typically 0.2-1.2  $\mu$ g/mL in the presence of 200ng/mL recombinant human Fas ligand.


**Predicted N-terminal:** Gln 26

**Reconstitution:** **Centrifuge vial prior to opening.** Add sterile distilled water to a concentration of 0.1 mg/mL and gently pipette the solution up and down the sides of the vial. **DO NOT VORTEX.** Allow several minutes for complete reconstitution.

**Storage & Stability:** Stable for up to 1 year from date of receipt at -20°C to -80°C  
After reconstitution, store working aliquots at -20°C to -80°C.  
**Avoid repeated freeze-thaw cycles.**

Measured by its ability to inhibit Fas Ligand induced apoptosis of Jurkat human acute T cell leukemia cells. The ED50 for this effect is typically 0.2-1.2  $\mu$ g/mL in the presence of 200ng/mL recombinant human Fas ligand.

SDS-PAGE



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



® **Cell Sciences**®  
65 Parker Street  
Unit 11  
Newburyport, MA 01950

Toll Free: 888-769-1246  
Phone: 978-572-1070  
Fax: 978-992-0298

E-mail: [info@cellsciences.com](mailto:info@cellsciences.com)  
Website: [www.cellsciences.com](http://www.cellsciences.com)